SCHEMBL4673928

SCHEMBL4673928

O=C(Cc1[nH]ccc1CCCCS(=O)(=O)c1ccccc1)C(=O)c1nn[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.41
NCEH1 Q6PIU2 1/20 0.41
HDAC1 Q13547 4/20 0.34
HDAC8 Q9BY41 3/20 0.34
HDAC2 Q92769 3/20 0.34
HDAC3 O15379 2/20 0.34
HDAC4 P56524 2/20 0.34
HDAC7 Q8WUI4 2/20 0.34
HDAC10 Q969S8 2/20 0.34
HDAC11 Q96DB2 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
HDAC9 Q9UKV0 2/20 0.34
HDAC5 Q9UQL6 2/20 0.34
KEAP1 Q14145 2/20 0.33
NFE2L2 Q16236 1/20 0.33
KCNH2 Q12809 1/20 0.31
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676036 0.87 CES1 (0.56) CES1NCEH1HDAC1HDAC8HDAC2
SCHEMBL4675470 0.84 HDAC1 (0.34) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL4678376 0.79 CES1 (0.33) CES1NCEH1KEAP1MMP13MMP1
SCHEMBL4678575 0.79 CES1 (0.43) CES1NCEH1HDAC1HDAC8HDAC2
SCHEMBL4672710 0.78 APOBEC3G (0.33) CES1NCEH1HDAC1HDAC8HDAC2
SCHEMBL5899367 0.78 CES1 (0.36) CES1NCEH1HDAC1HDAC8HDAC2
SCHEMBL4676664 0.78 CES1 (0.43) CES1NCEH1HDAC1HDAC8HDAC2
SCHEMBL4673282 0.77 CES1 (0.42) CES1NCEH1
SCHEMBL4671266 0.76 CES1 (0.36) CES1NCEH1HDAC1HDAC8HDAC2
SCHEMBL4676922 0.73 CES1 (0.43) CES1NCEH1HDAC1HDAC8HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885HDAC1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.